Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court’s decision denying ...

Real-time index price for TSX Composite ESG Index (TXSG), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Eli Lilly and Novo Nordisk are expected to announce price reductions for their weight-loss drugs as part of the TrumpRx ...

(Reuters) -Novo Nordisk is now offering up to $10 billion for Metsera, up from its prior offer of up to $8.5 billion, the ...

Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...

Large, Finance and Markets With one eye on Tuesday's U. local elections, stocks have been knocked back sharply from Monday's heady highs - partly on Palantir's 6% earnings-day drop and ahead of ...

Pfizer (PFE), one of the world’s oldest and most respected pharmaceutical companies, is currently facing significant stock ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $13.0 to $26.5 for Pfizer over the last 3 months.

Stock futures were on the rise on Monday ahead of another busy week for earnings. Roughly one-third of S&P 500-listed companies have yet to report third-quarter results, according to FactSet. Results ...

Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $30.0 for Pfizer during the past quarter. Looking at the volume ...